These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 28194724)

  • 1. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.
    Lener MS; Kadriu B; Zarate CA
    Drugs; 2017 Mar; 77(4):381-401. PubMed ID: 28194724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Modulators in Depression.
    Henter ID; de Sousa RT; Zarate CA
    Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
    McIntyre RS; Jain R
    CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New targets for rapid antidepressant action.
    Machado-Vieira R; Henter ID; Zarate CA
    Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
    Halaris A; Cook J
    Adv Exp Med Biol; 2023; 1411():487-512. PubMed ID: 36949323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
    Tomasetti C; Montemitro C; Fiengo ALC; Santone C; Orsolini L; Valchera A; Carano A; Pompili M; Serafini G; Perna G; Vellante F; Martinotti G; Giannantonio MD; Kim YK; Nicola MD; Bellomo A; Ventriglio A; Fornaro M; Berardis DD
    Curr Pharm Des; 2019; 25(4):381-387. PubMed ID: 30864501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
    Vasiliu O
    Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ketamine's antidepressant effect: literature review on clinical use].
    De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
    Encephale; 2014 Feb; 40(1):15-23. PubMed ID: 24434008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
    d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
    Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
    Krystal JH; Sanacora G; Duman RS
    Biol Psychiatry; 2013 Jun; 73(12):1133-41. PubMed ID: 23726151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
    Pereira VS; Joca SRL; Harvey BH; Elfving B; Wegener G
    Acta Neuropsychiatr; 2019 Oct; 31(5):258-265. PubMed ID: 31230597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.